Avidity biosciences announces inducement grants under nasdaq listing rule 5635(c)(4)

San diego , sept. 23, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that on september 20, 2024, the human capital management committee of avidity's board of directors granted non-qualified stock option awards to purchase an aggregate of 212,000 shares of its common stock and 106,000 restricted stock units ("rsus") to twenty-one (21) new non-executive employees under the avidity biosciences, inc. 2022 employment inducement incentive award plan (the "2022 inducement plan").
RNA Ratings Summary
RNA Quant Ranking